OREANDA-NEWS. September 16, 2016. Tissue Regenix's (TRX) investment story is built on dCELL, a versatile regenerative medical technology and its potential applications across the subsectors: cardiac, wound care and orthopaedics. The cardiac division has a proven technology with the broadest clinical experience, with 10 years of clinical follow-up data recently presented. We maintain our sum-of-the-parts valuation at ?338m.

We recently revisited a number of our key valuation assumptions to reflect the clarity on launch timeframes, associated costs and updated revenue guidance. We maintain our DCF valuation at ?338m or 44.4p per share. According to our model, the current price gives a free option on wound care, the most commercially advanced division, and does not reflect the full pipeline potential, which could ultimately be an acquisition target as a whole or by division.  

Click here to view the full report